Europharma debuts glutathione supplement featuring patented French technology to boost bioavailability

Europharma debuts glutathione supplement featuring patented French technology to boost bioavailability

EuroPharma has launched a patented, more bioavailable form of glutathione in the US market, the firm announced recently. With the announcement, the firm joins a number of companies advertsing their bioavailable forms of the antioxidant.

Slow melt technology

Branded as Clinical Glutathione, the supplement will be offered in a slow melt tablet, which is a key part of the technology. EuroPharma, manufacturer of the Terry Naturally branded line of supplements, has contracted with a French supplier to bring the ingredient to the US.  The ingredient’s special formulation boosts its bioavailability over standard glutathione formulations by as much as 230%, according to the company.

Glutathione historically has been unstable in oral supplementation. Healthy people should have a serum ratio of 90% non-oxidized, reduced glutathione (active) to 10% oxidized glutathione (inactive).  According to Europharma, one of the biggest challenges to delivering active (reduced) glutathione is that unprotected glutathione is rapidly oxidized by elemental exposure and digestion, even if it is enteric coated. Suppliers such as Kohjin and Kyowa Hakko have taken other formulation approaches to tackle this problem and recently have reported positive results in the blood uptake of non-oxidized glutathione. The patented French technology marketed by EuroPharma combines antioxidants and slow melt technology to prevent this degradation.

Underlying deficiency

“Oxygen is actually incredibly toxic unless you know how to handle it,” said Jacob Teitelbaum, MD, a member of EuroPharma’s scientific advisory board. “Glutathione is the major antioxidant in the body.  Your body makes less of it as you age, so by age 65 you have only about 50% of your original glutathione production.  That is one of the things that happens to people when they age; they rust, essentially,” he said.

Teitelbaum is an expert in the treatment of fibromyalgia and the glutathione level in a patient’s system is one of the key factors in that condition.  He said it figures into other conditions such as autoimmune disorders, too.

“I’ve said for decades one underlying things that’s going on is a glutathione deficiency. Because of the problems with oral supplementation, what we’ve done in the past is to give the glutathione intravenously. Now you can take a pill and have the same effect,” he said.

Related News

Kyowa’s Setria meets US Pharmacopeial Convention (USP) monograph for glutathione

Kyowa Hakko produces Setria, its branded form of glutathione, in a dedicated fermentation facility.

Glutathione study will boost ingredient's profile, supplier says

Kohjin presents evidence of blood uptake of its glutathione

Kohjin presents evidence of blood uptake of its glutathione

New data indicates oral supplementation can increase glutathione stores, influence immune function

New data indicates oral supplementation can increase glutathione stores, influence immune function

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.